Sartorius, 101000172, LipidBrick®

LipidBrick® is a novel range of proprietary cationic lipids dedicated to the formulation of LNPs for the development of mRNA-based vaccines and therapeutics.

LipidBrick® is a unique library composed of innovative proprietary imidazolium-based cationic lipids dedicated to the formulation of lipid nanoparticles (LNPs). These active lipids safeguard mRNA molecules and enhance the transfection ability of LNPs. Each LipidBrick® lipid is permanently charged; therefore, unlike ionizable lipids, it confers an overall positive charge to LNPs, which induces extra-hepatic tropism. In addition, delivery efficacy and biodistribution can be fine-tuned by screening the LipidBrick® library to select the most suitable LipidBrick® lipid for each specific application therapeutic need.
Key Benefits:
Efficient: Modulate LNP properties to adapt biodistribution to therapeutic goals.
Secure: Unique structure protected by an independent patent held by Polyplus (now part of Sartorius).
Time-Saving: In vitro and in vivo proof of concept studies have been successfully performed.
Flexible: Versatile library for selecting the best LipidBrick® for each application.

Specifications
Applications:
Application: Active cationic lipids for LNP formulation

Biological Information:
Molecule delivered: mRNA

Compliance Information:
Product Documentation: Protocol; Certificate of Analysis; Master Safety Data Sheet

General Specifications:
Amount of Reagent: LipidBrick® IM21.7c 250 mg

Storage Conditions:
Storage Conditions: -20 °C ± 5 °C